Fondaparinux
Arixtra
Factor Xa Inhibitor
NADAC/unit
$12.7720
No Shortage
Tier 1: 70.5%
4 Manufacturers
16 ANDAs
Fondaparinux prevents blood clots by inhibiting factor Xa, prescribed for atrial fibrillation and venous thromboembolism.
vs. brand Arixtra: Generic saves up to -28% per unit
Active Shortages
2025-09-29 Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc., Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
2025-09-29 Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc., Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
2025-09-29 Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc., Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
2025-09-29 Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc., Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Generic Manufacturers
DR REDDYS LABORATORIES LTDEUGIA PHARMA SPECIALITIES LTDJIANGSU HENGRUI PHARMACEUTICALS CO LTDMYLAN IRELAND LTDSCINOPHARM TAIWAN LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.